Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is a high-tech biopharmaceutical company listed on the ChiNext board of the Shenzhen Stock Exchange since 2014. The company specializes in the research, development, production, and sales of products for the diagnosis and treatment of allergic diseases. As a leader in the allergenic immunotherapy market in China, Wolwo is also expanding its research efforts into other areas, including stem cells and natural medicines, particularly antibiotics aimed at drug-resistant bacterial strains. Wolwo's main products include Dermatophagoides Farinae Drops, which are used for treating allergic rhinitis and asthma caused by dust mites, and Artemisia Annua Allergens Sublingual Immunotherapy Drops. The company emphasizes its strong research and development capabilities, which are crucial in the highly innovative pharmaceutical manufacturing industry. Wolwo's Dermatophagoides Farinae Drops are notable for being the only sublingual desensitization drug approved in China, providing a safe and convenient alternative to traditional injected therapies. The company's competitive edge is further reinforced by its unique product offerings and ongoing commitment to technological innovation.

The pharmaceutical manufacturing industry is highly innovative, while technological innovation and upgrading of medical products may bring revolutionary changes to the entire industry. Therefore, the decisive factors to occupy a leading position in the industry are independent research and development capabilities and technological innovation capabilities. The company owns a highly competitive R&D team with a reasonable age structure and relatively good stability that is able to grasp important development opportunities of technology update and product replacement. This assures continuity and foresight for Wolwo’s R&D. Until today, there are only 3 dust mite desensitization drugs approved by the Chinese National Medical Products Administration: Dermatophagoides Farinae Drops, Mites allergens ALK (503) D.p, and Novo-Helisen-Depot, most of which are injected subcutaneously, with the exception of Wolwo’s Dermatophagoides Farinae Drops，which is taken sublingually. This product is safe, easy to use, and high portable. Wolwo's product Artemisia Annua Allergens Sublingual Immunotherapy Drops was approved and issued by the Chinese National Medical Products Administration on 30 January 2021. According to the Chinese National Medical Products Administration's official website, there are by far no products of the same variety. Wolwo's competitiveness continue to lead the field.